KR102526287B1 - Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component - Google Patents
Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component Download PDFInfo
- Publication number
- KR102526287B1 KR102526287B1 KR1020200166781A KR20200166781A KR102526287B1 KR 102526287 B1 KR102526287 B1 KR 102526287B1 KR 1020200166781 A KR1020200166781 A KR 1020200166781A KR 20200166781 A KR20200166781 A KR 20200166781A KR 102526287 B1 KR102526287 B1 KR 102526287B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cricket
- inflammatory
- wrinkle
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 18
- 241000238820 Gryllus bimaculatus Species 0.000 title claims description 9
- 206010061218 Inflammation Diseases 0.000 title description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims description 17
- 102000029816 Collagenase Human genes 0.000 claims description 14
- 108060005980 Collagenase Proteins 0.000 claims description 14
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 229960002424 collagenase Drugs 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 244000063299 Bacillus subtilis Species 0.000 claims description 7
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 5
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 241000238814 Orthoptera Species 0.000 description 53
- 239000000047 product Substances 0.000 description 33
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000037303 wrinkles Effects 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 12
- -1 lipid peroxide Chemical class 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 10
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 10
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 10
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 230000002849 elastaseinhibitory effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 쌍별귀뚜라미 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 조성물에 관한 것으로, 본 발명의 쌍별귀뚜라미 추출물의 발효물은 항염 활성이 있으며 콜라게나아제 및 엘라스타아제 저해 활성이 우수하므로, 항염증 및 주름 개선용 조성물로 매우 유용하게 사용될 수 있을 것이다. The present invention relates to an anti-inflammatory and anti-wrinkle composition containing a fermented product of a cricket extract of the present invention as an active ingredient. Since it is excellent, it will be very useful as an anti-inflammatory and anti-wrinkle composition.
Description
본 발명은 쌍별귀뚜라미 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 조성물에 관한 것이다.The present invention relates to an anti-inflammatory and anti-wrinkle composition containing a fermented product of Ssangbyeol cricket extract as an active ingredient.
피부의 노화는 나이가 들어가면서 피부에 나타나게 되는 유형과 무형상의 변화를 통틀어 일컫는 것으로, 연령이 증가함에 따라 자연적으로 유발되는 내인성 생리적 노화와 장기간 자외선 노출에 의해 진행되는 외인성 광노화(photoaging)로 구분할 수 있다. 내인성 피부 노화의 임상적 특징은 피부가 얇아지고 탄력성이 감소하는 것이며, 조직학적 소견으로는 표피 및 진피의 두께가 얇아지고 혈관이 감소하며 진피 내의 섬유아세포의 수가 감소하는 것이다. 또한, 외인성 피부 노화인 광노화의 임상적 특징은 피부가 거칠어지고 탄력성이 없어지며, 불규칙한 색소 침착이 발생하고 깊은 주름살이 증가하는 것이다. Skin aging refers to both tangible and intangible changes that appear in the skin with age, and can be divided into endogenous physiological aging, which is naturally induced as age increases, and extrinsic photoaging, which is progressed by long-term exposure to ultraviolet rays. . The clinical features of endogenous skin aging are thinning of the skin and a decrease in elasticity, and histological findings include thinning of the epidermis and dermis, reduction of blood vessels, and a decrease in the number of fibroblasts in the dermis. In addition, the clinical features of extrinsic skin aging, photoaging, are rough skin, loss of elasticity, irregular pigmentation, and an increase in deep wrinkles.
주름의 생성 원인으로는 여러 가지가 보고되고 있는데, 우선 피부가 과다한 자외선에 노출되면 피부의 구성성분인 콜라겐(collagen) 분해가 촉진되어 피부가 탄력을 잃고 주름이 생성될 수 있다. 또한, 피부가 과도한 온도 변화, 습도 저하 또는 바람 등에 의해 지나치게 건조해지면 외부에 대한 방어벽으로서의 피부 기능이 저하되어 주름이 생기기도 한다. 그리고 피부가 활성 산소종이나 자유 라디칼에 노출되면 산화 작용에 의해 과산화 지질이 생성되고 그로 인해 콜라겐 등의 피부 구성 단백질이 변형되어 주름이 생길 수 있다. 이러한 외부적 요인과 내부적 요인에 의한 주름 발생을 억제하고자 다양한 화장품 조성물에 대한 연구가 이루어지고 있다. 하지만 화학 성분이 함유된 기능성 화장품의 경우, 피부 자극을 유발하여 민감성 피부에 적합하지 않은 문제점이 있는 바, 피부에 자극이 적고 친환경적인 천연 식물 유래의 기능성 화장품에 대한 관심이 집중되고 있다.Various causes of wrinkles have been reported. First, when the skin is exposed to excessive ultraviolet rays, the decomposition of collagen, which is a component of the skin, is promoted, and the skin loses elasticity and wrinkles may be generated. In addition, when the skin becomes excessively dry due to excessive temperature changes, low humidity, or wind, the function of the skin as a barrier against the outside is deteriorated, resulting in wrinkles. In addition, when the skin is exposed to reactive oxygen species or free radicals, lipid peroxide is produced by oxidation, and as a result, skin constituent proteins such as collagen are transformed, resulting in wrinkles. In order to suppress the occurrence of wrinkles caused by these external and internal factors, research on various cosmetic compositions has been conducted. However, in the case of functional cosmetics containing chemical components, there is a problem that causes skin irritation and is not suitable for sensitive skin, so attention is focused on functional cosmetics derived from natural plants that are less irritating to the skin and are eco-friendly.
쌍별귀뚜라미(Gryllus bimaculatus)는 메뚜기목 귀뚜라미과의 곤충으로, 생육기간이 90일 정도로 짧은 편이라 연중 실내 대량 사육이 가능하다. 갈색거저리의 유충인 밀웜처럼 애완동물의 먹이용이나 애완곤충용으로 사용되고 있으며, 최근 식품의약품안전처에서 한시적 식품원료로 인정받았다. The twin cricket ( Gryllus bimaculatus ) is an insect of the grasshopper order Cricketidae, and its growing period is as short as 90 days, so it can be reared in large quantities indoors throughout the year. Like mealworms, the larvae of brown mealworms, it is used for pet food or pet insects, and has recently been recognized as a temporary food ingredient by the Ministry of Food and Drug Safety.
한편, 한국등록특허 제2085577호에는 '쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물'이 개시되어 있고, 한국공개특허 제2020-0069250호에는 '쌍별귀뚜라미 추출물을 유효성분으로 포함하는 알코올에 의한 간손상 보호용 조성물'이 개시되어 있으나, 본 발명의 '쌍별귀뚜라미 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 조성물'에 대해서는 기재된 바가 없다.Meanwhile, Korean Patent No. 2085577 discloses 'a composition for preventing, improving or treating fatty liver disease containing Ssangbyeol cricket extract as an active ingredient', and Korean Patent Publication No. 2020-0069250 discloses 'Ssangbyeol cricket extract as an effective ingredient'. A composition for protecting against liver damage caused by alcohol' is disclosed, but nothing is described about the 'composition for anti-inflammatory and wrinkle improvement containing fermented extract of Ssangbyeol cricket extract as an active ingredient' of the present invention.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 쌍별귀뚜라미 추출물의 발효물의 항염 효과를 확인하였고, 콜라게나아제 및 엘라스타아제 저해 활성 분석을 통한 우수한 피부주름 개선 효과를 확인함으로써, 본 발명을 완성하였다.The present invention was derived from the above needs, and the inventors confirmed the anti-inflammatory effect of the fermented product of Ssangbyeol cricket extract, and confirmed the excellent skin wrinkle improvement effect through the analysis of collagenase and elastase inhibitory activities. The invention was completed.
상기 과제를 해결하기 위해, 본 발명은 쌍별귀뚜라미(Gryllus bimaculatus) 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 화장료 조성물을 제공한다.In order to solve the above problems, the present invention provides a cosmetic composition for anti-inflammatory and wrinkle improvement containing fermented product of Gryllus bimaculatus extract as an active ingredient.
또한, 본 발명은 쌍별귀뚜라미(Gryllus bimaculatus) 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for anti-inflammatory and wrinkle improvement containing fermented product of Gryllus bimaculatus extract as an active ingredient.
본 발명의 쌍별귀뚜라미 추출물의 발효물은 항염 활성을 가지며, 콜라게나아제 및 엘라스타아제 저해 활성이 우수하므로, 항염증 및 피부주름 개선을 위한 화장료 또는 건강기능식품 조성물의 소재로 유용하게 사용될 수 있을 것으로 기대된다. The fermented product of the Ssangbyeol cricket extract of the present invention has anti-inflammatory activity and excellent collagenase and elastase inhibitory activity, so it can be usefully used as a material for cosmetic or health functional food compositions for anti-inflammatory and skin wrinkle improvement It is expected that
도 1은 쌍별귀뚜라미 추출물에 B. subtilis JB PMB-18 균주를 접종하여 96시간 발효시키는 동안의 생균수(A) 및 pH(B)를 확인한 결과이다.
도 2는 쌍별귀뚜라미 추출물의 발효물의 RAW 264.7 세포에서의 세포 독성을 확인한 결과이다.
도 3은 LPS로 염증이 유도된 RAW 264.7 세포에서의 쌍별귀뚜라미 추출물의 발효물의 NO 생성 억제능을 확인한 결과이다.
도 4는 LPS로 염증이 유도된 RAW 264.7 세포에서의 쌍별귀뚜라미 추출물의 발효물의 COX-2(A) 및 iNOS(B) 발현 억제능을 확인한 결과로 β-actin에 대한 상대적 발현양으로 나타내었다.
도 5는 LPS로 염증이 유도된 RAW 264.7 세포에서의 쌍별귀뚜라미 추출물의 발효물의 염증성 사이토카인 생성 억제능을 확인한 결과로, A는 TNF-α의 생성량이고, B는 IL-1β의 생성량이며, C는 IL-6의 생성량이다.
도 6은 쌍별귀뚜라미 추출물의 발효물의 주름 개선 효과를 확인한 결과로, A는 콜라게나아제 저해 활성을 나타낸 것이고, B는 엘라스타아제 저해 활성을 나타낸 것이다. Figure 1 shows the results of confirming the number of viable cells (A) and pH (B) during fermentation for 96 hours by inoculating B. subtilis JB PMB-18 strain in the extract of Ssangbyeol cricket.
Figure 2 is the result of confirming the cytotoxicity in RAW 264.7 cells of the fermented product of the cricket pair extract.
Figure 3 is the result of confirming the NO production inhibition ability of the fermented product of the pair-byeol cricket extract in RAW 264.7 cells in which inflammation was induced by LPS.
Figure 4 shows the relative expression level for β-actin as a result of confirming the ability to inhibit COX-2 (A) and iNOS (B) expression of fermented cricket extracts in RAW 264.7 cells in which inflammation was induced by LPS.
Figure 5 is a result of confirming the inflammatory cytokine production inhibition ability of the fermented product of the cricket extract in RAW 264.7 cells in which inflammation was induced by LPS, A is the amount of TNF-α, B is the amount of IL-1β, and C is the amount of IL-1β. It is the production amount of IL-6.
6 is a result of confirming the anti-wrinkle effect of fermented cricket extract, A indicates collagenase inhibitory activity, and B indicates elastase inhibitory activity.
본 발명의 목적을 달성하기 위하여, 본 발명은 쌍별귀뚜라미(Gryllus bimaculatus) 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 화장료 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides a cosmetic composition for anti-inflammatory and wrinkle improvement containing fermented product of Gryllus bimaculatus extract as an active ingredient.
본 발명의 피부주름 개선용 화장료 조성물에서, 상기 쌍별귀뚜라미 추출물의 발효물은 쌍별귀뚜라미 추출물에 바실러스(Bacillus) 속의 균주를 접종하고 발효시켜 제조된 것으로, 상기 바실러스 속 균주는 바람직하게는 바실러스 서브틸리스(Bacillus subtilis) 균주일 수 있으며, 가장 바람직하게는 전주농생명소재연구원에서 보유하고 있는 Bacillus subtilis JB PMB-18 균주일 수 있으나, 이에 제한하는 것은 아니다. In the cosmetic composition for improving skin wrinkles of the present invention, the fermented product of the extract of the cricket pair is prepared by inoculating the extract of the cricket pair with a strain of the genus Bacillus and fermenting it. The strain of the genus Bacillus is preferably Bacillus subtilis. ( Bacillus subtilis ) It may be a strain, and most preferably, it may be a Bacillus subtilis JB PMB-18 strain possessed by Jeonju Agricultural Biomaterials Research Institute, but is not limited thereto.
또한, 상기 쌍별귀뚜라미 추출물의 발효물은 쌍별귀뚜라미 추출물에 Bacillus subtilis JB PMB-18 균주를 접종하여 30~40℃에서 1~3일 동안 발효시키는 것이 바람직하며, 37℃에서 2일 동안 발효시키는 것이 가장 바람직하나, 이에 한정하지 않는다. In addition, the fermented product of the twin cricket extract is preferably fermented at 30 to 40 ° C for 1 to 3 days by inoculating the Bacillus subtilis JB PMB-18 strain into the twin star cricket extract, and fermented at 37 ° C for 2 days is the most Preferred, but not limited thereto.
또한, 상기 쌍별귀뚜라미 추출물의 추출 용매는 당업계에 공지된 통상적인 추출용매를 사용할 수 있다. 바람직한 추출용매로는 C1~C4의 저급 알코올, 물 또는 이들의 혼합물을 용매일 수 있으며, 가장 바람직한 추출용매로는 물일 수 있으나, 이에 제한되지 않는다.In addition, as the extraction solvent of the Ssangbyeol cricket extract, a conventional extraction solvent known in the art may be used. A preferred extraction solvent may be a C 1 ~ C 4 lower alcohol, water, or a mixture thereof, and the most preferred extraction solvent may be water, but is not limited thereto.
상기 쌍별귀뚜라미 추출물의 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당업계에 공지된 모든 통상적인 방법을 이용하여 추출할 수 있고, 바람직한 추출방법은 열수 추출이나, 이에 제한되지 않는다. The extraction method of the twin cricket extract can be extracted using all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction, and a preferred extraction method is hot water extraction, Not limited.
또한, 상기 쌍별귀뚜라미 추출물은 추출처리에 의해 얻어지는 추출액; 추출액의 희석액 또는 농축액; 추출액을 건조하여 얻어지는 건조물; 조정제물; 또는 정제물 중 어느 하나를 포함할 수도 있다.In addition, the Ssangbyeol cricket extract is an extract obtained by extraction treatment; Dilutions or concentrates of extracts; dried product obtained by drying the extract; adjusted offerings; Or it may include any one of the purified water.
본 발명에 있어서, '주름 개선'이라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In the present invention, 'wrinkle improvement' refers to suppressing or inhibiting the formation of wrinkles on the skin, or alleviating already generated wrinkles.
본 발명의 쌍별귀뚜라미 추출물의 발효물은 NO, COX-2, iNOS 및 다양한 염증성 사이토카인의 생성을 억제할 수 있으며 콜라게나아제 및 엘라스타아제의 활성을 저해하는 활성이 우수한 것이 특징이다.The fermented product of the cricket extract of the present invention can suppress the production of NO, COX-2, iNOS and various inflammatory cytokines, and is characterized by excellent activity of inhibiting the activities of collagenase and elastase.
본 발명의 주름 개선용 화장료 조성물은 크림, 유연화장수, 영양화장수, 팩, 에센스, 헤어토닉, 샴푸, 린스, 헤어 컨디셔너, 헤어 트리트먼트, 젤, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 밀크로션, 모이스처로션, 영양로션, 마사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 영양에센스, 선스크린, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디 로션 및 바디 클렌저로 이루어지는 군으로부터 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않는다. 이들 각 제형으로 이루어진 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다. The cosmetic composition for improving wrinkles of the present invention is cream, softening lotion, nutrient lotion, pack, essence, hair tonic, shampoo, rinse, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, milk lotion , Moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, foundation, nutrient essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, any one selected from the group consisting of body lotion and body cleanser It may have a formulation of, but is not limited thereto. The cosmetic composition composed of each of these formulations may contain various bases and additives necessary and appropriate for formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component etc. can be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydro propellants such as carbon, propane butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
본 발명의 화장료 조성물의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
또한, 본 발명은 쌍별귀뚜라미(Gryllus bimaculatus) 추출물의 발효물을 유효성분으로 함유하는 항염증 및 주름 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for anti-inflammatory and wrinkle improvement containing fermented product of Gryllus bimaculatus extract as an active ingredient.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods. Active ingredients can be appropriately used depending on their purpose of use (prevention or improvement). In general, when preparing food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the type of health functional food. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, and vitamin complexes, and includes all health foods in a conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 통상적으로 첨가되는 성분을 포함할 수 있다. 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention can be made into food, particularly functional food. The functional food of the present invention may contain ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when prepared as a drink, natural carbohydrates or flavors may be included as additional ingredients in addition to active ingredients. The natural carbohydrates are monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.) or sugar alcohols (eg, maltose, sucrose, etc.) , xylitol, sorbitol, erythritol, etc.) are preferred. As the flavoring agent, natural flavoring agents (eg, thaumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonic acid It may further contain a carbonation agent used in beverages and the like. The ratio of the components to be added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 이에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail by examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited thereto.
제조예 1. 쌍별귀뚜라미 추출물 제조Preparation Example 1. Preparation of Ssangbyeol cricket extract
쌍별귀뚜라미는 (주)MG내추럴에서 구매하여 실험에 사용하였다. 분쇄한 쌍별귀뚜라미 500 g을 3차 멸균 증류수 5 ℓ에 혼합하여 80℃에서 3시간 동안 열수 추출하였다. 이후, 8,000 rpm으로 15분간 원심분리하고 상층액을 취해 여과지(Adventec, No.2)를 이용하여 필터한 뒤, 동결건조하여 총 59.09 g의 추출물을 수득하였다. Paired crickets were purchased from MG Natural and used in the experiment. 500 g of crushed crickets were mixed with 5 L of tertiary sterilized distilled water, followed by hot water extraction at 80°C for 3 hours. Thereafter, centrifugation was performed at 8,000 rpm for 15 minutes, and the supernatant was filtered using filter paper (Adventec, No. 2), followed by lyophilization to obtain a total of 59.09 g of extract.
제조예 2. 쌍별귀뚜라미 추출물의 발효물 제조Preparation Example 2. Preparation of fermented product of Ssangbyeol cricket extract
상기 방법으로 제조된 쌍별귀뚜라미 추출물에 바실러스 서브틸리스(Bacillus subtilis)를 접종하고 발효시켜 쌍별귀뚜라미 추출물의 발효물을 제조하였다. 발효에 사용한 균주는 (재)전주농생명소재연구원에서 보유하고 있는 B. subtilis JB PMB-18 균주이며, 100 ㎖의 NB(Nutrient Broth) 배지에 접종하여 37℃, 200 rpm으로 24시간 동안 전배양하고 5,000 rpm으로 10분간 원심분리하여 상층액을 제거한 뒤, PBS로 1회 세척하여 발효를 위한 균주를 준비하였다. 100 ㎖의 증류수에 제조예 1의 쌍별귀뚜라미 추출물 0.5 g을 넣고, 준비한 균주를 2%(v/v)의 농도로 접종하여 37℃, 200 rpm으로 48시간 동안 발효시켰다. 이후, 8,000 rpm으로 20분간 원심분리하여 상층액을 회수하고 0.45 ㎛ 필터에 여과한 뒤 동결건조하여 쌍별귀뚜라미 추출물의 발효물을 수득하였다. Bacillus subtilis was inoculated into the cricket extract prepared by the above method and fermented to prepare a fermented product of the cricket extract. The strain used for fermentation is the B. subtilis JB PMB-18 strain owned by Jeonju Agricultural Biomaterials Research Institute, inoculated into 100 ml of NB (Nutrient Broth) medium, and pre-cultured for 24 hours at 37 ° C and 200 rpm After removing the supernatant by centrifugation at 5,000 rpm for 10 minutes, the strain was prepared for fermentation by washing once with PBS. 0.5 g of the cricket extract of Preparation Example 1 was added to 100 ml of distilled water, and the prepared strain was inoculated at a concentration of 2% (v/v) and fermented at 37° C. and 200 rpm for 48 hours. Thereafter, the supernatant was collected by centrifugation at 8,000 rpm for 20 minutes, filtered through a 0.45 μm filter, and lyophilized to obtain a fermented product of the extract of the cricket pair.
실시예 1. 생균수 및 pH 변화 측정Example 1. Measurement of viable cell count and pH change
제조예 1의 쌍별귀뚜라미 추출물에 B. subtilis JB PMB-18 균주를 접종하여 96시간 발효시키는 동안의 생균수 및 pH를 측정하였다. 생균수는 시료 1 ㎖에 멸균 식염수로 10배씩 단계별 희석한 후 100 ㎕를 취하여 NB 고체배지에 도말하고 37℃에서 24시간 동안 배양하여 생성된 콜로니 수를 계수하였다. pH는 시료 1 ㎖을 취하여 pH 미터기를 이용하여 측정하였다. The B. subtilis JB PMB-18 strain was inoculated into the cricket extract of Preparation Example 1, and the viable cell count and pH were measured during fermentation for 96 hours. The viable cell count was diluted stepwise by 10 times with sterile saline in 1 ml of the sample, and then 100 μl was spread on NB solid medium and cultured at 37° C. for 24 hours, and the number of colonies produced was counted. pH was measured using a pH meter by taking a sample of 1 ml.
그 결과, 쌍별귀뚜라미 추출물의 발효 초기 생균수는 5.42 log CFU/㎖이였고, 발효 48시간에 9.88 log CFU/㎖로 가장 많은 생균수를 나타내는 것을 확인하였다. 또한, 발효 전 쌍별귀뚜라미 추출물의 pH는 6.5였으며 발효하는 동안 점점 증가하여 발효 종료시에는 pH 8.2를 나타내는 것을 확인하였다(도 1). As a result, it was confirmed that the number of viable cells in the initial stage of fermentation was 5.42 log CFU/ml, and the highest number of viable cells was 9.88 log CFU/ml after 48 hours of fermentation. In addition, the pH of the Ssangbyeol cricket extract before fermentation was 6.5, and it was confirmed that it gradually increased during fermentation and reached pH 8.2 at the end of fermentation (FIG. 1).
따라서, 48시간 동안 발효시키는 것이 균의 증식이 가장 활발한 것으로 확인하고 이후 실험을 진행하였다. Therefore, it was confirmed that fermentation for 48 hours was the most active growth of bacteria, and then the experiment was conducted.
실시예 2. 세포독성 분석Example 2. Cytotoxicity assay
마우스 대식세포주인 RAW 264.7 세포는 한국세포주은행(Korea Cell Line Bank, KCLB, No. 40071)에서 분양받아 사용하였으며, 10% FBS(fetal bovine serum, USA)가 함유된 DMEM(Dulbecco Modified Eagle Medium, Korea) 배지를 사용하여 37℃, 5% CO2 항온기에서 배양하였고, 3일에 한 번씩 계대배양을 수행하였다. RAW 264.7 세포를 5×104 cells/웰로 96 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 각 웰에 100 ㎕씩 넣고 24시간 배양하였다. 배양액을 제거하고 5 mg/㎖의 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)를 각 웰에 넣고 4시간 동안 배양한 후, 상등액을 제거하고 DMSO(dimethyl sulfoxide)를 100 ㎕씩 분주하여 각 웰에 생성된 결정체를 모두 용해시키고, 마이크로플레이트 리더기(Multiskan Go, Thermo Scientific, USA)를 이용하여 570 nm에서 흡광도를 측정하였고, 하기 계산식을 통해 세포생존율을 분석하였다. RAW 264.7 cells, a mouse macrophage cell line, were purchased and used from the Korea Cell Line Bank (Korea Cell Line Bank, KCLB, No. 40071) and DMEM (Dulbecco Modified Eagle Medium, Korea) containing 10% FBS (fetal bovine serum, USA). ) culture medium at 37° C., 5% CO 2 in an incubator, and subculture was performed once every 3 days. RAW 264.7 cells were seeded in a 96-well plate at 5×10 4 cells/well and cultured for 24 hours to stabilize. 100 μl of the fermentation product was added to each well and incubated for 24 hours. Remove the culture medium, add 5 mg/mL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to each well, incubate for 4 hours, remove the supernatant, and DMSO ( dimethyl sulfoxide) was dispensed by 100 μl to dissolve all crystals generated in each well, and absorbance was measured at 570 nm using a microplate reader (Multiskan Go, Thermo Scientific, USA), and cell viability was calculated using the following formula. analyzed.
세포생존율(%)=[시료처리군의 흡광도/대조군의 흡광도]X100Cell viability (%) = [absorbance of sample treatment group / absorbance of control group]
그 결과, 50, 100, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물은 RAW 264.7 세포에서 90% 이상의 생존율을 보여, 세포독성을 나타내지 않는 것을 확인하였다(도 2). As a result, it was confirmed that the fermented products of 50, 100, 500, and 1,000 μg/ml of cricket extracts showed a viability of 90% or more in RAW 264.7 cells, and did not exhibit cytotoxicity (FIG. 2).
실시예 3. 항염 활성 분석Example 3. Anti-inflammatory activity assay
LPS(lipopolysaccharide)로 염증이 유도된 마우스 대식세포주인 RAW 264.7 세포에서의 쌍별귀뚜라미 추출물의 발효물의 항염 활성을 분석하였다. The anti-inflammatory activity of the fermented product of the cricket extract was analyzed in RAW 264.7 cells, a mouse macrophage cell line in which inflammation was induced by LPS (lipopolysaccharide).
(1) NO 생성 억제능 측정(1) Measurement of NO production inhibition ability
NO(nitric oxide)는 면역계에서 방어분자로서 중요한 역할을 하지만, 과도하게 증가하면 NO를 생성하는 세포자신과 주위의 세포와 조직, 기관에 손상을 초래하여 면역질환을 포함한 관절염, 기관지염, 다발성 경화증과 같은 병적반응을 일으킨다. 따라서, 쌍별귀뚜라미 추출물의 발효물의 항염 활성을 분석하기 위하여 NO 생성 억제능을 측정하였다. RAW 264.7 세포를 5×104 cells/웰로 96 웰 플레이트에 분주하여 24 시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 생성된 NO의 양은 그리스 시약(Griess Reagent System, Promega, USA)을 이용하여 세포배양액 중에 존재하는 NO2 -의 형태로 측정하였다. 세포배양 상등액 50 ㎕에 그리스 시약 100 ㎕를 처리하고 30분 내에 540 nm 파장에서 흡광도를 측정하였다.NO (nitric oxide) plays an important role as a defense molecule in the immune system, but if it is excessively increased, it causes damage to the NO-producing cells themselves and surrounding cells, tissues, and organs, leading to diseases such as arthritis, bronchitis, multiple sclerosis, and autoimmune diseases. cause the same pathological reaction. Therefore, in order to analyze the anti-inflammatory activity of the fermented product of the Ssangbyeol cricket extract, the NO production inhibitory ability was measured. RAW 264.7 cells were seeded in a 96-well plate at 5×10 4 cells/well, cultured for 24 hours to stabilize, and then 50, 100, 500, and 1,000 μg/ml of D. cricket extract diluted in serum-free DMEM medium. The fermentation product was pretreated for 2 hours and then treated with LPS (1 μg/ml) and cultured for 24 hours. The amount of NO produced was measured in the form of NO 2 - present in the cell culture medium using a grease reagent (Griess Reagent System, Promega, USA). 50 μl of the cell culture supernatant was treated with 100 μl of grease reagent, and absorbance was measured at a wavelength of 540 nm within 30 minutes.
그 결과, LPS 단독 처리군의 NO 생성량은 대조군 대비 현저하게 증가하였고, 쌍별귀뚜라미 추출물의 발효물 처리군의 NO 생성량은 감소하였으며 특히, 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물 처리군은 LPS 단독 처리군 대비 약 79.1%, 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물 처리군 대비 약 67% 가량의 NO 생성 억제능을 보이는 것을 확인하였다(도 3).As a result, the amount of NO production in the LPS-only treatment group was significantly increased compared to the control group, and the amount of NO production in the fermented product treatment group of the cricket extract of 1,000 μg/ml was decreased. It was confirmed that the inhibition of NO production was about 79.1% compared to the treated group and about 67% compared to the 1,000 μg/ml twin-byeol cricket extract treated group (FIG. 3).
(2) COX-2 및 iNOS 생성 억제능 측정(2) Measurement of COX-2 and iNOS production inhibitory ability
COX-2(Cyclooxygenase-2) 및 iNOS(Inducible nitric oxide synthases)는 대식세포에서 염증반응에 의해 생성되는 NO 및 PGE2(Prostaglandin2)의 생성 경로에 관여하는 단백질이다. COX-2는 정상 생리학적인 조건에서는 발현되지 않지만 암 발생 촉진물질(tumor promotor), 성장인자(growth factor) 및 사이토카인(cytokine) 등에 의해 발현된다고 알려져 있다. iNOS는 LPS, IFN-γ, IL-1 및 TNF-α 등의 자극에 의해 발현되며 NO를 생성하는데 관여한다고 알려져 있다. RAW 264.7 세포를 1×106 cells/웰로 6 웰 플레이트에 분주하여 24 시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 100, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 이후, 배지를 12,000 rpm으로 3분간 원심분리하여 얻어진 펠렛에서 RNA를 추출하고 정량하였다. 1 ㎍의 RNA로 cDNA를 합성하여 프라이머, 멸균수 및 마스터 믹스(master mix)와 혼합하여 총 20 ㎕의 반응액으로 PCR을 수행하였고, 사용한 프라이머는 아래 표 1과 같다. Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthases (iNOS) are proteins involved in the production pathway of NO and PGE2 (Prostaglandin 2) produced by inflammatory responses in macrophages. COX-2 is not expressed under normal physiological conditions, but is known to be expressed by tumor promoters, growth factors, and cytokines. iNOS is expressed by stimuli such as LPS, IFN-γ, IL-1 and TNF-α and is known to be involved in NO production. RAW 264.7 cells were seeded in a 6-well plate at 1×10 6 cells/well, cultured for 24 hours to stabilize, and fermented products of 100, 500, and 1,000 μg/ml of D. cricket extract diluted in serum-free DMEM medium. was pre-treated for 2 hours and then treated with LPS (1 μg/ml) and cultured for 24 hours. Thereafter, the medium was centrifuged at 12,000 rpm for 3 minutes, and RNA was extracted and quantified from the resulting pellet. PCR was performed with a total of 20 μl of reaction solution by synthesizing cDNA with 1 μg of RNA and mixing with primers, sterile water and a master mix, and the primers used are shown in Table 1 below.
그 결과, LPS 단독 처리군의 COX-2 및 iNOS의 발현양은 대조군 대비 현저하게 증가하였고, 쌍별귀뚜라미 추출물의 발효물 처리군의 발현양은 감소하였다. 특히, 100 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물 처리군은 쌍별귀뚜라미 추출물 처리군 대비 COX-2 발현은 약 55% 가량 감소하였고, iNOS 발현은 약 46.1% 가량 감소하여, 쌍별귀뚜라미 추출물의 발효물이 쌍별귀뚜라미 추출물보다 COX-2 및 iNOS 생성 억제능이 우수한 것을 확인하였다(도 4).As a result, the expression levels of COX-2 and iNOS in the LPS-only treated group were significantly increased compared to the control group, and the expression levels in the fermented cricket extract-treated group were decreased. In particular, 100 μg/ml fermented cricket extract treatment group decreased COX-2 expression by about 55% and iNOS expression decreased by about 46.1% compared to the fermented cricket extract treatment group. It was confirmed that the COX-2 and iNOS production inhibitory ability was superior to that of this paired cricket extract (FIG. 4).
(3) 염증성 사이토카인의 생성 억제능 측정(3) Measurement of the ability to inhibit the production of inflammatory cytokines
RAW 264.7 세포를 5×105 cells/웰로 24웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 이후, 12,000 rpm으로 3분간 원심분리하여 얻어진 상층액으로 염증성 사이토카인 TNF-α(tumor necrosis factor alpha), IL-1β(Interleukin 1 beta) 및 IL-6(Interleukin 6)의 생성량을 측정하였다. 각 사이토카인은 ELISA 키트(R&D systems Inc., USA)를 이용하여 정량하였으며 standard에 대한 표준곡선 R2 값이 0.9 이상이었다. RAW 264.7 cells were seeded in a 24-well plate at 5×10 5 cells/well and cultured for 24 hours to stabilize. The fermentation product was pretreated for 2 hours and then treated with LPS (1 μg/ml) and cultured for 24 hours. Thereafter, the amount of inflammatory cytokines TNF-α (tumor necrosis factor alpha), IL-1β (Interleukin 1 beta) and IL-6 (Interleukin 6) produced in the supernatant obtained by centrifugation at 12,000 rpm for 3 minutes was measured. Each cytokine was quantified using an ELISA kit (R&D systems Inc., USA), and the standard curve R 2 value for the standard was 0.9 or more.
그 결과, LPS 단독 처리군은 대조군 대비 TNF-α, IL-1β 및 IL-6 사이토카인 생성량이 현저하게 증가하였고, 쌍별귀뚜라미 추출물의 발효물 처리군의 염증성 사이토카인 생성량은 감소하는 것을 확인하였다. 또한, 500 및 1,000 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 처리했을 때 아무것도 처리하지 않은 대조군과 유사한 수준의 사이토카인 생성량이 검출되는 것을 확인하였다. 특히, 쌍별귀뚜라미 추출물보다 쌍별귀뚜라미 추출물의 발효물의 염증성 사이토카인 생성 억제능이 현저하게 우수한 것을 확인하였다(도 5).As a result, it was confirmed that the production of TNF-α, IL-1β, and IL-6 cytokines in the LPS-only treatment group was significantly increased compared to the control group, and the production of inflammatory cytokines in the fermented product treatment group of the paired cricket extract was decreased. In addition, it was confirmed that cytokine production at a level similar to that of the untreated control was detected when fermented products of 500 and 1,000 μg/ml of cricket extract were treated. In particular, it was confirmed that the inflammatory cytokine production inhibition ability of the fermented product of the twin-byeol cricket extract was remarkably superior to that of the twin-byeol cricket extract (FIG. 5).
실시예 4. 주름개선 효과 분석Example 4. Analysis of anti-wrinkle effect
콜라게나아제 및 엘라스타아제는 세포외 기질 단백질을 분해하여 피부의 주름 생성을 촉진시키는 효소이므로, 본 발명의 쌍별귀뚜라미 추출물의 발효물에 의한 콜라게나아제 및 엘라스타아제 저해 활성을 측정하였다. Since collagenase and elastase are enzymes that degrade extracellular matrix proteins to promote skin wrinkles, the collagenase and elastase inhibitory activities of the fermented extract of the cricket cricket of the present invention were measured.
(1) 콜라게나아제의 저해 활성 측정(1) Measurement of collagenase inhibitory activity
콜라게나아제(collagenase) 저해 활성은 EnzChek® 젤라티나아제/콜라게나아제 어세이 키트(ThermoFisher Scientific)를 이용하여 분석하였다. 100 및 500 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 준비한 다음, 키트 내 기질과 콜라게나아제 효소를 96 웰 플레이트에 넣고 25℃에서 1시간 동안 반응시켰다. 형광 플레이트 분석기를 이용하여 흡수 파장은 495 nm이고, 발광 파장은 515 nm로 하는 조건으로 형광강도를 측정하였고, 콜라게나아제 저해 활성은 하기 계산식을 통해 산출하였다.Collagenase inhibitory activity was analyzed using the EnzChek® Gelatinase/Collagenase Assay Kit (ThermoFisher Scientific). Fermented products of 100 and 500 μg/ml of cricket extract were prepared, and the substrate and collagenase enzyme in the kit were placed in a 96-well plate and reacted at 25° C. for 1 hour. Using a fluorescence plate analyzer, the fluorescence intensity was measured under the condition that the absorption wavelength was 495 nm and the emission wavelength was 515 nm, and the collagenase inhibitory activity was calculated through the following formula.
콜라게나아제 저해 활성(%) = {1-(S-B)/C}×100Collagenase inhibitory activity (%) = {1- (S-B) / C} × 100
(S: 시료의 흡광도, B: blank의 흡광도, C: control의 흡광도)(S: absorbance of sample, B: absorbance of blank, C: absorbance of control)
그 결과, 쌍별귀뚜라미 추출물은 콜라게나아제 저해 활성이 거의 없는 반면,쌍별귀뚜라미 추출물의 발효물은 콜라게나아제 저해 활성이 매우 우수한 것을 확인하였다(도 6A).As a result, it was confirmed that the fermented cricket extract had very good collagenase inhibitory activity (FIG. 6A).
(2) 엘라스타아제의 저해 활성 측정(2) Measurement of elastase inhibitory activity
엘라스타아제(elastase) 저해 활성은 EnzChek® 엘라스타아제 어세이 키트(ThermoFisher Scientific)를 이용하여 분석하였다. 50, 100 및 500 ㎍/㎖의 쌍별귀뚜라미 추출물의 발효물을 준비한 다음, 키트 내 기질과 엘라스타아제 효소를 96 웰 플레이트에 넣고 25℃에서 50분간 반응시켰다. 형광 플레이트 분석기를 이용하여 흡수 파장은 505 nm이고, 발광 파장은 515 nm로 하는 조건으로 형광강도를 측정하였고, 엘라스타제 저해 활성은 하기 계산식을 통해 산출하였다. Elastase inhibitory activity was analyzed using EnzChek ® Elastase Assay Kit (ThermoFisher Scientific). Fermented products of 50, 100, and 500 μg/ml of cricket extract were prepared, and then the substrate and elastase enzyme in the kit were placed in a 96-well plate and reacted at 25° C. for 50 minutes. The fluorescence intensity was measured using a fluorescence plate analyzer under the condition that the absorption wavelength was 505 nm and the emission wavelength was 515 nm, and the elastase inhibitory activity was calculated through the following formula.
엘라스타아제 저해 활성(%) = {1-(S-B)/C}×100Elastase inhibitory activity (%) = {1-(S-B)/C}×100
(S: 시료의 흡광도, B: blank의 흡광도, C: control의 흡광도)(S: absorbance of sample, B: absorbance of blank, C: absorbance of control)
그 결과, 쌍별귀뚜라미 추출물은 엘라스타아제 저해 활성이 거의 없는 반면,쌍별귀뚜라미 추출물의 발효물은 엘라스타아제 저해 활성이 농도 의존적으로 증가하는 것을 확인하였다(도 6B).As a result, it was confirmed that the elastase inhibitory activity of the fermented product of the cricket extract was increased in a concentration-dependent manner (Fig. 6B).
상기의 결과를 통해 쌍별귀뚜라미 추출물은 주름 개선 효과가 거의 없는 반면, 쌍별귀뚜라미 추출물의 발효물은 주름 개선 효과가 우수한 것을 알 수 있었다. Through the above results, it was found that the fermented product of the extract of the cricket twine had an excellent anti-wrinkle effect, while the extract of the cricket twine had almost no effect on wrinkles.
<110> JEONJU BIOMATERIALS INSTITUTE <120> Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component <130> PN20305 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 1 ctctacaaca actccatcct 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 2 attctgcagc catttccttc 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 3 cgaaacgctt cacttccaa 19 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 4 tgagcctata ttgctgtggc t 21 <210> 5 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 5 cggttccgat gccctgaggc tctt 24 <210> 6 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 6 cgtcacactt catgatggaa ttga 24 <110> JEONJU BIOMATERIALS INSTITUTE <120> Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component <130> PN20305 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> artificial sequence <220> <223> primer <400> 1 ctctacaaca actccatcct 20 <210> 2 <211> 20 <212> DNA <213> artificial sequence <220> <223> primer <400> 2 attctgcagc catttccttc 20 <210> 3 <211> 19 <212> DNA <213> artificial sequence <220> <223> primer <400> 3 cgaaacgctt cacttccaa 19 <210> 4 <211> 21 <212> DNA <213> artificial sequence <220> <223> primer <400> 4 tgacctata ttgctgtggc t 21 <210> 5 <211> 24 <212> DNA <213> artificial sequence <220> <223> primer <400> 5 cggttccgat gccctgaggc tctt 24 <210> 6 <211> 24 <212> DNA <213> artificial sequence <220> <223> primer <400> 6 cgtcacactt catgatggaa ttga 24
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200166781A KR102526287B1 (en) | 2020-12-02 | 2020-12-02 | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200166781A KR102526287B1 (en) | 2020-12-02 | 2020-12-02 | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220077991A KR20220077991A (en) | 2022-06-10 |
KR102526287B1 true KR102526287B1 (en) | 2023-04-27 |
Family
ID=81986414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200166781A KR102526287B1 (en) | 2020-12-02 | 2020-12-02 | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102526287B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102489767B1 (en) * | 2022-03-23 | 2023-01-18 | 이재홍 | Composition for anti-inflammation, regenerating skin and anti-wrinkle comprising ethanol extract of fermented Gryllus bimaculatus as effective component |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101752451B1 (en) | 2017-04-14 | 2017-07-03 | 에스폴리오(주) | Cosmetic composition having anti-inflammatory activity |
KR102041860B1 (en) * | 2017-12-21 | 2019-11-07 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturizing comprising Gryllus bimaculatus extract as effective component |
KR102070802B1 (en) | 2017-07-28 | 2020-01-29 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturizing comprising Gryllus bimaculatus extract as effective component |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130134097A (en) * | 2012-05-30 | 2013-12-10 | 경북대학교 산학협력단 | Preventive and therapeutic compositions for skin inflammation comprising cricket extracts |
KR101809451B1 (en) * | 2015-02-05 | 2018-01-18 | 이삼구 | Crickets for improved antioxidant, antiaging activity, skin beauty and cosmetic composition comprising the same |
-
2020
- 2020-12-02 KR KR1020200166781A patent/KR102526287B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101752451B1 (en) | 2017-04-14 | 2017-07-03 | 에스폴리오(주) | Cosmetic composition having anti-inflammatory activity |
KR102070802B1 (en) | 2017-07-28 | 2020-01-29 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturizing comprising Gryllus bimaculatus extract as effective component |
KR102041860B1 (en) * | 2017-12-21 | 2019-11-07 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturizing comprising Gryllus bimaculatus extract as effective component |
Also Published As
Publication number | Publication date |
---|---|
KR20220077991A (en) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6670166B2 (en) | Cosmetics | |
JP2020532560A (en) | Cosmetic composition containing extract of Dendrobium candidam flower | |
KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR102354412B1 (en) | Cosmetic Composition Comprising Lactobacillus Fermented product of Mixed Flower Extracts as Active Ingredient | |
KR20220082393A (en) | Composition Comprising Lactobacillus rhamnosus, Culture Fluid, or Culture Fluid Extract thereof with Anti-Inflammatory, Moisturizing, Skin Barrier, and Skin Cell Regeneration Property as Active Ingredient | |
KR102243982B1 (en) | Composition for improving skin troubles comprising mortierella oil as an active ingredient | |
WO2019124862A1 (en) | Skin wrinkle prevention and improvement composition containing schisandra chinensis extract as active ingredient | |
KR20190063549A (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
KR102526287B1 (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
JP2023171950A (en) | Anti-aging agent, antioxidant, anti-inflammatory agent, and whitening agent, as well as cosmetic | |
KR20210155989A (en) | Composition Comprising Lactobacillus sakei, Culture Fluid, or Culture Fluid Extract thereof with Anti-Wrinkling and Elasticity, Skin Cell Regeneration, and Skin Barrier Property as Active Ingredient | |
KR102017132B1 (en) | Cosmetic composition comprising a mixed fermentation extract of cinnamomum verum and angelica dahurica | |
KR102226131B1 (en) | Composition for skin moisturizing comprising extract of fermented Setaria italica as effective component | |
KR20200057126A (en) | Composition for Regenerating Skin and Enhancing Hair Growth Comprising Apigenin | |
KR101960571B1 (en) | Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract | |
KR102298533B1 (en) | Antianging cosmetic composition comprising green tea fermented extract fermented by inoculating lactococcus lactis strain | |
KR102288902B1 (en) | Cosmetic composition for anti-wrinkle and enhancing elasticity comprising fermented extract of Phragmites Communis | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
KR20220141191A (en) | Composition for Skin Whitening, Moisturizing, Strengthening Skin Barrier, Skin Cell Regeneration, and Anti-Wrinkle Property Comprising Fermented Extract of Broussonetia kazinoki as Active Ingredient | |
KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR102105672B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR102406981B1 (en) | Composition for improving skin wrinkle comprising extract of Semiaquilegia adoxoides having antioxidant and anti-inflammatory activity as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |